ArticlePloS one2014
Prostate stromal cells express the progesterone receptor to control cancer cell mobility.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.Prostate cancer and prostatic diseases · 2021Article
- Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.BMC cancer · 2020Article
- In Vitro Vascular Network Modified to Function as Culture Platform and Angiogenic Induction Potential Test for Cancer Cells.International journal of molecular sciences · 2020Article
- The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.PloS one · 2020Article
- Structure and Function of the Nuclear Receptor Superfamily and Current Targeted Therapies of Prostate Cancer.Cancers · 2019Review
- Review
- Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment.Molecular cancer · 2019Review
- Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia.Research and reports in urology · 2019Review
- Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores.Scientific reports · 2018Article
- Progesterone Receptors in Prostate Cancer: Progesterone receptor B is the isoform associated with disease progression.Scientific reports · 2018Article
- Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.Oncology reports · 2016Article
- Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.Oncotarget · 2015Article
- High progesterone receptor expression in prostate cancer is associated with clinical failure.PloS one · 2015Article
- p53 mediated apoptosis in osteosarcoma MG-63 cells by inhibition of FANCD2 gene expression.International journal of clinical and experimental medicine · 2015Article
- Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (Review).Oncology letters · 2014Article
- Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundReciprocal interactions between epithelium and stroma play vital roles for prostate cancer development and progression. Enhanced secretions of cytokines and growth factors by cancer associated fibroblasts in prostate tumors create a favorable microenvironment for cancer cells to grow and metastasize. Our previous work showed that the progesterone receptor (PR) was expressed specifically in prostate stromal fibroblasts and smooth muscle cells. However, the expression levels of PR and its impact to tumor microenvironment in prostate tumors are poorly understood.
methodsImmunohistochemistry assays are applied to human prostate tissue biopsies. Cell migration, invasion and proliferation assays are performed using human prostate cells. Real-time PCR and ELISA are applied to measure gene expression at molecular levels.
resultsImmunohistochemistry assays showed that PR protein levels were decreased in cancer associated stroma when compared with paired normal prostate stroma. Using in vitro prostate stromal cell models, we showed that conditioned media collected from PR positive stromal cells inhibited prostate cancer cell migration and invasion, but had minor suppressive impacts on cancer cell proliferation. PR suppressed the secretion of stromal derived factor-1 (SDF-1) and interlukin-6 (IL-6) by stromal cells independent to PR ligands. Blocking PR expression by siRNA or supplementation of exogenous SDF-1 or IL-6 to conditioned media from PR positive stromal cells counteracted the inhibitory effects of PR to cancer cell migration and invasion.
conclusionsDecreased expression of the PR in cancer associated stroma may contribute to the elevated SDF-1 and IL-6 levels in prostate tumors and enhance prostate tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.